Clinical trials: Hepatitis, Viral, Human
Hepatitis B
Hepsera Versus Hepsera Plus Lamivudine for Treatment of Chronic Hepatitis B in Patients With Normal ALT
This project is a randomized, open-label trial of adefovir dipivoxil (Hepsera) and lamivudine combination therapy versus adefovir dipivoxil (Hepsera) monotherapy.
- Trial name
- NCT00230477
- Testing
- Hepsera, Hepsera and lamivudine
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Washington
Exposure to Hepatitis B Virus
Safety and Efficacy Study of Adjuvanted Prophylactic Hepatitis B Vaccine
There is a need for more effective and better-tolerated hepatitis B vaccines for low responder high-risk populations including patients with renal impairment and/or diabetes mellitus and those aged over 40 years.
- Trial name
- NCT01951677
- Testing
- HBsAg, PreS HBsAg, Advax-1(TM)
- Where
- Australia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
Hepatitis C, Chronic, Substance Abuse, Intravenous
Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261)
Previous intravenous drug abusers with chronic hepatitis C who are under substitution therapy (buprenorphine, methadone) will be treated with PegIntron and Rebetol according to the approved European labeling.
- Trial name
- SUPPORT (NCT00726557)
- Testing
- PegIntron (pegylated interferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 246 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)
This is a 2 part study of the safety, pharmacokinetics and pharmacodynamics of MK-6325 in HCV-infected participants. Part I of the study will be for Genotype (GT) 1 HCV-infected participants who will be randomized to receive…
- Trial name
- NCT01329913
- Testing
- MK-6325
- Volunteers
- 36 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis B
Long-term Study on Anti-HBV Effect of Tenofovir and Resistance Surveillance in Asian-American Adult Patients
This is a Phase IV, open-label, single-arm, 96 week community-based observational study evaluating the antiviral efficacy, safety, and tolerability of TDF in HBV mono-infected Asian-American adults who had completed 48 week…
- Trial name
- NCT01267162
- Where
- 5 sites in United States
- Volunteers
- 31 people
- Sponsor
- Medical Procare PLLC
Chronic Hepatitis C
Long Term Vitamin D Therapy in HCV Treated Patients
Treatment of hepatitis C virus (HCV) infection was carried out using pegylated interferon (PEG-IFN), ribavirin (RBV) and vitamin D (vit D) for 48 weeks in HCV genotypes 4a subjects.
- Trial name
- VD-HCV (NCT01997203)
- Testing
- Vitamin D
- Where
- 2 sites in Egypt
- Volunteers
- 100 people
- Sponsor
- Dr. Nadia AbdelAaty AbdelKader
Chronic Hepatitis B
Observational Study on Patients With Chronic Hepatitis B
The study was conducted to evaluate the effect of anti-viral treatment on long-term outcome on patients with chronic hepatitis B.
- Trial name
- NCT02167503
- Where
- 14 sites in China
- Volunteers
- 10,000 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Healthy Participants
A Study to Investigate the Potential Pharmacokinetic Interactions Between Phenytoin or Carbamazepine and Telaprevir
The purpose of this study is to investigate the potential pharmacokinetic (what the body does to the drug) interactions between multiple doses of phenytoin 200 mg every 12 hours or carbamazepine 200 mg every 12 hours and…
- Trial name
- NCT01635829
- Testing
- Telaprevir, Phenytoin, Carbamazepine
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Janssen Infectious Diseases BVBA
Hepatitis C
Pegaferon and Ribavirin for Hepatitis C
The purpose of this study is to evaluate the safety and efficacy of a locally produced 40KD pegylated interferon alpha-2a (Pegaferon) in patients with hepatitis C.
- Trial name
- NCT01137383
- Testing
- Pegaferon (pegylated interferon alpha 2a) + ribavirin
- Where
- 2 sites in Iran
- Volunteers
- 108 people
- Sponsor
- Tehran University of Medical Sciences
Chronic Hepatitis B
Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B
The primary objectives of this study are to evaluate the safety, tolerability and antiviral activity of selgantolimod (formerly GS-9688) in virally suppressed chronic hepatitis B (CHB) adults on oral antiviral (OAV) agents.
- Trial name
- NCT03491553
- Testing
- Selgantolimod, Hepatitis B virus (HBV) OAV Therapy
- Where
- 2 sites in United States, New Zealand
- Volunteers
- 48 people
- Sponsor
- Gilead Sciences
Hepatitis C Virus Infection
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection
The primary objective of this study is to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) for 12 weeks in participants with chronic hepatitis C virus…
- Trial name
- NCT02722837
- Testing
- SOF/VEL
- Where
- 15 sites in Russia, Sweden
- Volunteers
- 119 people
- Sponsor
- Gilead Sciences
Hepatitis B
Hepatitis B Vaccine for Non-responders
In the current study, the investigators study the efficacy of the HBAI20 vaccine to induce seroprotection in registered non-responders (adults who were previously vaccinated with the HBVaxPro-10μg but did not achieve…
- Trial name
- NCT03415672
- Testing
- HBVaxPro, HBAI20
- Where
- 3 sites in Belgium, Netherlands
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Hepatitis B
Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age
Primary Objective: To describe the persistence of Hep B antibodies (Ab) at 12 to 18 months of age following a three-dose infant primary series vaccination of either Hexaxim®/Hexyon®/Hexacima® or Infanrix® hexa at 2, 4 and 6…
- Trial name
- NCT02610348
- Testing
- DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines, DTaP-HB-IPV and Pneumococcal polysaccharide vaccines
- Where
- 2 sites in Thailand
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hepatitis C, Hepatitis B
Noninvasive Staging of Liver Fibrosis: MR vs Ultrasound
Liver fibrosis is an important public health problem, with a substantial morbidity and mortality due to progression to cirrhosis and hepatocellular carcinoma. All causes of chronic liver disease may lead to fibrosis.
- Conditions
- Hepatitis C, Hepatitis B, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
- Trial name
- ELF (NCT02044523)
- Testing
- Transient elastography, acoustic radiation force impulse, magnetic resonance elastography
- Where
- Canada
- Volunteers
- 108 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Diagnostic, Chronic Viral Hepatitis B
Sysmex-XN 20 Analyser to Assess Lymphocyte Subsets and Other Haematological Parameters in Chronic/Acute Viral Infections
The XN-20, is a full blood count (FBC) analyser with an extended differential counting and flagging System. The XN-Series' individual channels allow real-time reflex analysis, and uses a two stage process to classify the white…
- Conditions
- Diagnostic, Chronic Viral Hepatitis B, Chronic Hepatitis C, Chronic HIV Infection
- Trial name
- SASA (NCT03495570)
- Testing
- blood draw
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- University College, London
Hepatitis B
Consistency of 3 Consecutive Lots of a Novel HBV Vaccine With Single-blind Safety Evaluation Using Engerix™-B as Control
The purpose of the present study is to evaluate the immunogenicity and safety of three consecutive production lots of the novel adjuvanted HBV vaccine.
- Trial name
- NCT00697866
- Testing
- HBV-MPL vaccine 208129, Engerix™-B
- Volunteers
- 951 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C, Chronic
Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)
The main purpose of the study is to determine the antiviral efficacy and evaluate the safety and tolerability of sofosbuvir/ velpatasvir (SOF/VEL) and sofosbuvir/ velpatasvir/ voxilaprevir (SOF/VEL/VOX) used to treat individuals…
- Trial name
- SHARED3 (NCT03888729)
- Testing
- sofosbubir/velpatasvir, sofosbubir/velpatasvir/voxilaprevir
- Where
- Rwanda
- Volunteers
- 100 people
- Sponsor
- Partners in Health
Chronic Hepatitis B
Assessment of Treatment Adherence and Associated Factors in Chronic HepB Patients Supported by HBVCare
Adherence to chronic Hepatitis B (HBV) treatment and regular follow-up visits is essential for preventing dangerous complications, yet adherence rates in Vietnam remain low due to barriers in patient awareness and geographic…
- Trial name
- HBVCare (NCT07540637)
- Testing
- HBVCare Mobile App
- Where
- 2 sites in Vietnam
- Volunteers
- 70 people
- Sponsor
- Institute of Gastroenterology and Hepatology, Vietnam
De Novo Autoimmune Hepatitis
De Novo Autoimmune Hepatitis in Pediatric Liver Transplantation
The purpose of this study is to provide insights into the cause, development and effects of de novo autoimmune hepatitis so that prevention and treatment strategies can be developed in order to reduce post-liver transplant…
- Trial name
- NCT02056054
- Testing
- Pediatric transplant subject with d-AIH, Pediatric transplant subject with acute rejection, Pediatric transplant subject with chronic rejection
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Yale University
Chronic Hepatitis B
A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects
The goal of this clinical trial is to learn if ALG-000184 is safe, well-tolerated, and works to treat chronic hepatitis B virus (HBV) infection.
- Trial name
- NCT04536337
- Testing
- ALG-000184, Entecavir
- Where
- 10 sites in Australia, China and 4 more
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Aligos Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.